Literature DB >> 23888327

Lack of recall response to Tax in ATL and HAM/TSP patients but not in asymptomatic carriers of human T-cell leukemia virus type 1.

Sharrón L Manuel1, Mohit Sehgal, John Connolly, George Makedonas, Zafar K Khan, Jay Gardner, Michael R Betts, Pooja Jain.   

Abstract

PURPOSE &
METHODS: The immunopathogenic mechanisms responsible for debilitating neurodegenerative and oncologic diseases associated with human T-cell leukemia virus type 1 (HTLV-1) are not fully understood. Quality of cytotoxic T lymphocytes (CTLs) is being increasingly associated with the outcome of persistent HTLV-1 infection. In this respect, a patient cohort (from HTLV-1 endemic region) consisting of seronegative controls (controls), asymptomatic carriers (ACs), and patients with adult T-cell leukemia (ATL) or HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) was analyzed for CD8(+) T cells polyfunctionality in response to the viral antigen Tax.
RESULTS: Compared to ACs, ATL and HAM/TSP patients had lower frequency and polyfunctionality of CTLs in response to Tax suggesting dysfunction of CD8(+) T cells in these individuals. As an underlying mechanism, programmed death-1 (PD-1) receptor was found to be highly unregulated in Tax-responsive as well as total CD8(+) T cells from ATL and HAM/TSP but not from ACs and directly correlated with the lack of polyfunctionality in these individuals. Further, PD-1 expression showed a direct whereas MIP-1α expression had an indirect correlation with the proviral load providing new insights about the immunopathogenesis of HTLV-associated diseases. Additionally, we identified key cytokine signatures defining the immune activation status of clinical samples by the luminex assay.
CONCLUSIONS: Collectively, our findings suggest that reconstitution of fully functional CTLs, stimulation of MIP-1α expression, and/or blockade of the PD-1 pathway are potential approaches for immunotherapy / therapeutic vaccine against HTLV-mediated diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23888327      PMCID: PMC3784618          DOI: 10.1007/s10875-013-9918-x

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  65 in total

1.  Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP.

Authors:  M Nagai; K Usuku; W Matsumoto; D Kodama; N Takenouchi; T Moritoyo; S Hashiguchi; M Ichinose; C R Bangham; S Izumo; M Osame
Journal:  J Neurovirol       Date:  1998-12       Impact factor: 2.643

2.  Human T cell leukemia virus type I (HTLV-I)-specific CD8+ CTL clones from patients with HTLV-I-associated neurologic disease secrete proinflammatory cytokines, chemokines, and matrix metalloproteinase.

Authors:  W E Biddison; R Kubota; T Kawanishi; D D Taub; W W Cruikshank; D M Center; E W Connor; U Utz; S Jacobson
Journal:  J Immunol       Date:  1997-08-15       Impact factor: 5.422

3.  Reduced frequency, diversity, and function of human T cell leukemia virus type 1-specific CD8+ T cell in adult T cell leukemia patients.

Authors:  Tomohiro Kozako; Naomichi Arima; Shingo Toji; Izumi Masamoto; Masaki Akimoto; Heiichiro Hamada; Xiao-Fang Che; Hiroshi Fujiwara; Kakushi Matsushita; Masahito Tokunaga; Koichi Haraguchi; Kimiharu Uozumi; Susumu Suzuki; Toshiro Takezaki; Shunro Sonoda
Journal:  J Immunol       Date:  2006-10-15       Impact factor: 5.422

4.  Population dynamics of immune responses to persistent viruses.

Authors:  M A Nowak; C R Bangham
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

5.  Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression.

Authors:  Henry Radziewicz; Chris C Ibegbu; Marina L Fernandez; Kimberly A Workowski; Kamil Obideen; Mohammad Wehbi; Holly L Hanson; James P Steinberg; David Masopust; E John Wherry; John D Altman; Barry T Rouse; Gordon J Freeman; Rafi Ahmed; Arash Grakoui
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

6.  Fucoidan therapy decreases the proviral load in patients with human T-lymphotropic virus type-1-associated neurological disease.

Authors:  Natsumi Araya; Katsunori Takahashi; Tomoo Sato; Tatsufumi Nakamura; Chika Sawa; Daisuke Hasegawa; Hitoshi Ando; Satoko Aratani; Naoko Yagishita; Ryoji Fujii; Hiroshi Oka; Kusuki Nishioka; Toshihiro Nakajima; Naoki Mori; Yoshihisa Yamano
Journal:  Antivir Ther       Date:  2011

7.  Lack of association of Human T-cell lymphotrophic virus type 1(HTLV-1) infection and rheumatoid arthritis in an endemic area.

Authors:  D Sebastian; S Nayiager; D Y York; G M Mody
Journal:  Clin Rheumatol       Date:  2003-02       Impact factor: 2.980

8.  Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease.

Authors:  S Jacobson; H Shida; D E McFarlin; A S Fauci; S Koenig
Journal:  Nature       Date:  1990-11-15       Impact factor: 49.962

9.  Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals.

Authors:  G Rosignoli; C H Lim; M Bower; F Gotch; N Imami
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

10.  HTLV-1 tax specific CD8+ T cells express low levels of Tim-3 in HTLV-1 infection: implications for progression to neurological complications.

Authors:  Lishomwa C Ndhlovu; Fabio E Leal; Aaron M Hasenkrug; Aashish R Jha; Karina I Carvalho; Ijeoma G Eccles-James; Fernanda R Bruno; Raphaella G S Vieira; Vanessa A York; Glen M Chew; R Brad Jones; Yuetsu Tanaka; Walter K Neto; Sabri S Sanabani; Mario A Ostrowski; Aluisio C Segurado; Douglas F Nixon; Esper G Kallas
Journal:  PLoS Negl Trop Dis       Date:  2011-04-26
View more
  8 in total

1.  HTLV-1 Infection and Neuropathogenesis in the Context of Rag1-/-γc-/- (RAG1-Hu) and BLT Mice.

Authors:  Rashida Ginwala; Breanna Caruso; Zafar K Khan; Ajinkya Pattekar; Glen M Chew; Michael J Corley; Ronak Loonawat; Steven Jacobson; Sreesha Sreedhar; Lishomwa C Ndhlovu; Pooja Jain
Journal:  J Neuroimmune Pharmacol       Date:  2017-04-04       Impact factor: 4.147

2.  In vivo and in vitro immunogenicity of novel MHC class I presented epitopes to confer protective immunity against chronic HTLV-1 infection.

Authors:  Ria Mulherkar; Aykan Karabudak; Rashida Ginwala; Xiaofang Huang; Aileen Rowan; Ramila Philip; Edward L Murphy; Danielle Clements; Lishomwa C Ndhlovu; Zafar K Khan; Pooja Jain
Journal:  Vaccine       Date:  2018-07-10       Impact factor: 3.641

3.  An altered maturation and adhesion phenotype of dendritic cells in diseased individuals compared to asymptomatic carriers of human T cell leukemia virus type 1.

Authors:  Sharrón L Manuel; Mohit Sehgal; Zafar K Khan; James J Goedert; Michael R Betts; Pooja Jain
Journal:  AIDS Res Hum Retroviruses       Date:  2013-07-19       Impact factor: 2.205

Review 4.  Human T cell leukemia virus type 1 and Zika virus: tale of two reemerging viruses with neuropathological sequelae of public health concern.

Authors:  DeGaulle I Chigbu; Pooja Jain; Brenndan L Crumley; Dip Patel; Zafar K Khan
Journal:  J Neurovirol       Date:  2019-01-28       Impact factor: 3.739

5.  Myocyte enhancer factor (MEF)-2 plays essential roles in T-cell transformation associated with HTLV-1 infection by stabilizing complex between Tax and CREB.

Authors:  Pooja Jain; Alfonso Lavorgna; Mohit Sehgal; Linlin Gao; Rashida Ginwala; Divya Sagar; Edward W Harhaj; Zafar K Khan
Journal:  Retrovirology       Date:  2015-02-27       Impact factor: 4.602

6.  Clinical trial of a humanized anti-IL-2/IL-15 receptor β chain in HAM/TSP.

Authors:  Yoshimi Enose-Akahata; Unsong Oh; Joan Ohayon; Bridgette Jeanne Billioux; Raya Massoud; Bonita R Bryant; Ashley Vellucci; Nyater Ngouth; Irene Cortese; Thomas A Waldmann; Steven Jacobson
Journal:  Ann Clin Transl Neurol       Date:  2019-07-05       Impact factor: 4.511

7.  Phenotypic and Functional Analyses Guiding Combination Immune Checkpoint Immunotherapeutic Strategies in HTLV-1 Infection.

Authors:  Danielle M Clements; Brenndan Crumley; Glen M Chew; Elijah Davis; Roberta Bruhn; Edward L Murphy; Lishomwa C Ndhlovu; Pooja Jain
Journal:  Front Immunol       Date:  2021-03-09       Impact factor: 7.561

Review 8.  T cell receptor repertoire analysis in HTLV-1-associated diseases.

Authors:  Annaliese Clauze; Yoshimi Enose-Akahata; Steven Jacobson
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.